Trials / Withdrawn
WithdrawnNCT03677115
Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- China Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration.
Detailed description
The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration. The effects of dexmedetomidine have only been compared at lower doses. This trial examined the effect of greater dose of dexmedetomidine on thoracic paravertebral block analgesia duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine | combination of ropivacaine and dexmedetomidine 20 ug every time |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
- First posted
- 2018-09-19
- Last updated
- 2021-11-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03677115. Inclusion in this directory is not an endorsement.